['metastatic pancreatic cancer']
['folfirinox', 'lv5fu2', 'folfiri.3', 'gemcitabine']

        Inclusion Criteria:

          -  Metastatic disease

          -  At least one mesurable lesion according to RECIST V1.1 criteria

          -  No prior chemotherapy (excepted if there is at least on lestion out of the irradition
             area)

          -  Age > 18 years. A favorable adviced by an onco geriatrician would be mandatory for
             inclusion of patients older than 75 older

          -  Performance statut (WHO) 0-1

          -  Polynyclear ≥ 1500/mm3

          -  Bilirubine ≤ 1,5 fois la LSN, creatinin < 120μmol / L

          -  Signed informed consent form

        Exclusion Criteria:

          -  Another type of pancreas tumor, as endocrine tumor ou with acinous cells

          -  Ampulloma

          -  Cerebral or meningeal metastasis

          -  Gilbert disease

          -  Neuropathie > or = grade 1

          -  Study treatments contraindication

          -  Uncontrolled diarrhoea or inflamatory disease of colon or rectum, or bowel obstruction
             or bowel sub-obstruction no resolved with specific treatment

          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant
             disease prevent patient to receive study Cancer within the 5 years before inclusion,
             except for int situ cancer of the neck of the uterus or basal cell skin cancer

          -  Significant previous cardiac and respiratory disease

          -  Patient included in an other therapeutic study with experimental treatment

          -  Pregnancy or breast feeding

          -  Patient depreved of freedom or under gardianship

          -  Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule
      